市场调查报告书
商品编码
1463684
南美洲和中美洲新生儿筛检市场预测至 2030 年 - 区域分析 - 按产品类型(试剂和检测试剂盒及仪器)、技术、测试类型和最终用户(医院和诊所以及诊断实验室)South & Central America Newborn Screening Market Forecast to 2030 - Regional Analysis - by Product Type (Reagents and Assay Kits, and Instruments), Technology, Test Type, and End User (Hospitals and Clinics, and Diagnostic Laboratories) |
2022年,南美洲和中美洲新生儿筛检市场价值为5,808万美元,预计到2030年将达到10,064万美元;预计 2022 年至 2030 年CAGR为 7.1%。
新生儿基因筛检推动南美洲和中美洲新生儿筛检市场
随着人们对疾病遗传原因的认识不断加深以及医疗保健技术的进步,对新生儿进行全面基因筛检的需求正在增加。因此,新生儿筛检市场的公司正在开发创新、经济高效的筛检解决方案。 Yescarta 和 Zynteglo 是针对大 B 细胞淋巴瘤和 β 地中海贫血的授权基因治疗的两个例子。此外,技术的出现赋予了识别出生时疾病遗传倾向的能力,为个人化医疗保健铺平了道路,与精准医疗的更广泛趋势保持一致。
孕期遗传疾病筛检的重点还在于及早发现与妊娠相关的问题。新一代定序有助于新生儿产前筛检,检测所有染色体的非整倍体(如唐氏症和 21 三体性)或部分染色体异常(重复或缺失)的敏感度超过 95%。萤光原位杂交(FISH)用于检测镰状细胞性贫血等单基因疾病;它还有助于有效的植入前遗传学诊断。使用母体血浆进行无细胞胎儿 DNA 等非侵入性操作是基因检测的最新进展。胚胎 DNA 可以根据大小差异与母体 DNA 片段区分开来。使用萤光探针的即时 PCR、鸟枪定序(Solexa 或 Illumina)或大规模标靶平行定序可用于检查与胎儿健康状况相关的 DNA。如果进一步研究这种类型的基因筛检,这将使医生能够透过某些药物疗法(药物遗传学)提供早期分子干预,并在物理和化学上改造细胞、组织和器官。因此,婴儿遗传性疾病筛检方法的进步为整个新生儿筛检市场带来了巨大的潜力。
南美洲和中美洲新生儿筛检市场概述
南美洲和中美洲的新生儿筛检市场分为巴西、阿根廷以及南美洲和中美洲的其他地区。南美洲和中美洲是一个由 20 个在地理区域、人口、经济、社会、种族和发达的医疗保健系统方面多元化的国家组成的地区。与高收入国家相比,巴西、阿根廷和其他南美洲和中美洲国家接受的新生儿筛检计画相对较少。这主要是由于该地区各国的经济、技术和后勤限制以及社会、文化和政治背景的差异。联邦新生儿筛检 (NBS) 计画目前包括六种疾病:先天性甲状腺功能低下症、囊性纤维化、半乳糖血症测试、生物素酶缺乏症和该地区的先天性肾上腺增生症。此外,该地区的新生儿筛检计画和能力正在不断改进。智利、哥斯达黎加、古巴和乌拉圭的长期 NBS 计划涵盖了 99% 以上的新生儿。巴西、墨西哥和阿根廷的计画增加了筛选小组,但需要教育、后续行动、立法和管理方面的改进。
巴西于 2001 年启动了全国 NBS 计划,参考中心覆盖了 80% 以上的新生儿。该计画包括六种主要病症:苯酮尿症、先天性甲状腺功能低下症、血红蛋白疾病、囊性纤维化、先天性肾上腺增生和生物素酶缺乏症。巴西国家新生儿筛检计画的目标是在未来几年内达到 100% 的活产率。该国还在一些州透过串联质谱仪 (TMS) 筛检实施了针对其他代谢紊乱的扩展 NBS (ENBS)。巴西政府当局于 2021 年 6 月通过了一项法律,要求所有州在 2022 年 6 月之前实施 ENBS,并逐步扩大该计划以涵盖溶酶体疾病、免疫缺陷和脊髓性肌肉萎缩症。因此,由于新计划的实施、医疗保健覆盖率的提高、国家统计局新法律的颁布、疾病范围的扩大以及公众参与度的提高,该国在过去几年中实现了显着且持续的增长。政府和公共卫生当局。增加 NBS/ENBS 计划的采用可促进新生儿的早期诊断和治疗,这已被证明是改善患者健康结果的第一步。
南美洲和中美洲新生儿筛检市场收入及 2030 年预测(百万美元)
南美洲和中美洲新生儿筛检市场细分
南美洲和中美洲新生儿筛检市场根据产品类型、技术、测试类型、最终用户和国家进行细分。
根据产品类型,南美洲和中美洲新生儿筛检市场分为试剂、检测试剂盒和仪器。到2022 年,试剂和检测试剂盒细分市场将在南美洲和中美洲新生儿筛检市场中占据更大份额。酶检测。仪器部分细分为新生儿疾病筛检仪器、脉搏血氧仪、新生儿听力筛检仪器和其他仪器。
在技术方面,南美洲和中美洲新生儿筛检市场分为串联质谱(TMS)、分子检测、免疫检测和酵素检测、脉搏血氧饱和度筛检技术和其他技术。 2022 年,脉搏血氧饱和度筛检技术领域占据南美洲和中美洲新生儿筛检市场最大份额。
根据测试类型,南美洲和中美洲新生儿筛检市场分为干血斑测试、听力筛检测试、危重先天性心臟病(CCHD)测试和其他测试类型。 2022 年,干血斑检测领域占据南美洲和中美洲新生儿筛检市场最大份额。
依最终用户划分,南美洲和中美洲新生儿筛检市场分为医院、诊所和诊断实验室。 2022 年,医院和诊所细分市场在南美洲和中美洲新生儿筛检市场中占据更大份额。
根据国家/地区,南美洲和中美洲新生儿筛检市场分为巴西、阿根廷以及南美洲和中美洲其他地区。 2022 年,巴西在南美洲和中美洲新生儿筛检市场占据主导地位。
Bio-Rad Laboratories Inc、Masimo Corp、Medtronic Plc、PerkinElmer Inc 和 Waters Corp 是南美洲和中美洲新生儿筛检市场的一些领先公司。
表中的内容
The South & Central America newborn screening market was valued at US$ 58.08 million in 2022 and is expected to reach US$ 100.64 million by 2030; it is estimated to grow at a CAGR of 7.1% from 2022 to 2030.
Genetic Screening of Newborns Fuels the South & Central America Newborn Screening Market
The demand for comprehensive genetic screening of newborns is rising with the deepening knowledge about the genetic causes of medical conditions and advancements in healthcare technologies. As a result, companies in the newborn screening market are developing innovative, cost-effective screening solutions. Yescarta and Zynteglo are two examples of authorized gene treatments for large B-cell lymphoma and beta-thalassemia. Further, the emergence of technologies conferring an ability to identify genetic predispositions to diseases at birth pave the way for personalized healthcare, aligning with the broader trend of precision medicine.
Screening for genetic diseases during pregnancy also focuses on the early detection of pregnancy-related problems. Next-generation sequencing aids in the prenatal screening of neonates with a sensitivity of above 95% for detecting aneuploidies (such as Down syndrome and Trisomy 21) or partial chromosomal abnormalities (duplications or deletions) in all chromosomes. Fluorescence in-situ hybridization (FISH) is employed to detect monogenic illnesses such as sickle cell anemia; it also aids in an effective preimplantation genetic diagnosis. Noninvasive procedures such as the cell-free fetal DNA approach using maternal plasma are the recent advancements in genetic tests. The embryonic DNA can be distinguished from maternal DNA pieces based on differences in their sizes. Real-time PCR with fluorescent probes, shotgun sequencing (Solexa or Illumina), or huge targeted parallel sequencing can be used to examine DNA associated with fetal medical conditions. This would allow doctors to provide early molecular interventions with certain pharmacological therapies (pharmacogenetics) and to transform cells, tissues, and organs physically and chemically if this type of genetic screening is further researched. Thus, advancements in methods for screening infants for genetic disorders hold immense potential for the overall newborn screening market.
South & Central America Newborn Screening Market Overview
The newborn screening market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. South & Central America is a region comprising 20 diversified countries in terms of geographic area, demographics, economy, society, ethnicity, and developing healthcare systems. Brazil, Argentina, and other South & Central American countries receive a comparatively low number of newborn screening programs than higher-income nations. This is mainly due to the economic, technical, and logistical constraints and differences in the social, cultural, and political backgrounds of each country in the region. The federal NewBorn Screening (NBS) program currently includes six conditions: Congenital Hypothyroidism, Cystic Fibrosis, galactosemia test, biotinidase deficiency, and Congenital Adrenal Hyperplasia in the region. Moreover, the newborn screening programs and capabilities in the region are continuously improving. Longstanding NBS programs in Chile, Costa Rica, Cuba, and Uruguay cover over 99% of newborns. The programs in Brazil, Mexico, and Argentina have increased their screening panels but require education, follow-up, legislation, and management improvements.
Brazil started its nationwide NBS program in 2001 with reference centers that covered more than 80% of newborns. This program includes six main conditions: Phenylketonuria, Congenital Hypothyroidism, hemoglobinopathies, Cystic Fibrosis, Congenital Adrenal Hyperplasia, and biotinidase deficiency. The National Neonatal Screening Program in Brazil is targeting to reach 100% of live births over the next few years. The country has also implemented the Extended NBS (ENBS) for other metabolic disorders through tandem mass spectrometer (TMS) screening in a few states. A law was passed in June 2021 by the government authority of Brazil, mandating that all states implement ENBS by June 2022, with a progressive expansion of the program to include lysosomal diseases, immunodeficiencies, and spinal muscular atrophy. Thus, the country has witnessed significant and sustained growth in the last few years, owing to the implementation of new programs, a rise in medical healthcare coverage, the enactment of new NBS laws, the expansion of the disease panel, and the higher involvement of government and public health authorities. Increasing the adoption of NBS/ENBS programs promotes early diagnosis and treatment in neonates, which prove to be the first step to improving health outcomes for patients.
South & Central America Newborn Screening Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Newborn Screening Market Segmentation
The South & Central America newborn screening market is segmented based on product type, technology, test type, end user, and country.
Based on product type, the South & Central America newborn screening market is bifurcated into reagents and assay kits, and instruments. The reagents and assay kits segment held a larger South & Central America newborn screening market share in 2022. The reagents and assay kits segment is subsegmented into DNA-based assays, and immunoassays and enzymatic assays. Instruments segment is subsegmented into newborn disorder screening instruments, pulse oximeters, newborn hearing screening instruments, and other instruments.
In terms of technology, the South & Central America newborn screening market is categorized into tandem mass spectrometry (TMS), molecular assays, immunoassays and enzymatic assay, pulse oximetry screening technology, and other technologies. The pulse oximetry screening technology segment held the largest South & Central America newborn screening market share in 2022.
Based on test type, the South & Central America newborn screening market is categorized into dry blood spot test, hearing screen test, critical congenital heart diseases (CCHD) test, and other test types. The dry blood spot test segment held the largest South & Central America newborn screening market share in 2022.
By end user, the South & Central America newborn screening market is segmented into hospitals and clinics and diagnostic laboratories. The hospitals and clinics segment held a larger South & Central America newborn screening market share in 2022.
Based on country, the South & Central America newborn screening market is categorized into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America newborn screening market in 2022.
Bio-Rad Laboratories Inc, Masimo Corp, Medtronic Plc, PerkinElmer Inc, and Waters Corp are some of the leading companies operating in the South & Central America newborn screening market.
Table of Content